Zogenix, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZGNX research report →
Companywww.zogenix.com
Zogenix, Inc. , a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases.
- CEO
- Stephen Farr
- IPO
- 2010
- Employees
- 327
- HQ
- Emeryville, CA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -6.30
- P/S
- 0.00
- P/B
- 8.00
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.08%
- Op Margin
- -259.56%
- Net Margin
- -278.39%
- ROE
- -82.90%
- ROIC
- -56.92%
Growth & Income
- Revenue
- $81.69M · 498.77%
- Net Income
- $-227,413,000 · -8.61%
- EPS
- $-4.24 · -8.72%
- Op Income
- $-212,032,000
- FCF YoY
- -3.62%
Performance & Tape
- 52W High
- $26.90
- 52W Low
- $11.03
- 50D MA
- $23.18
- 200D MA
- $17.40
- Beta
- 0.90
- Avg Volume
- 3.10M
Get TickerSpark's AI analysis on ZGNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 7, 22 | BREITMEYER JAMES B | sell | 6,250 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 20,000 |
| Mar 7, 22 | BREITMEYER JAMES B | other | 1,250 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 9,375 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 10,000 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 22,000 |
| Mar 7, 22 | BREITMEYER JAMES B | sell | 9,000 |
| Mar 7, 22 | Stutts Mary E. | sell | 22,000 |
| Mar 7, 22 | Stutts Mary E. | sell | 20,000 |
| Mar 7, 22 | BOCK LOUIS C | sell | 20,000 |
Our ZGNX Coverage
We haven't published any research on ZGNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZGNX Report →